Most pharma boards are funding the wrong kind of AI.
They want chatbots that talk to HCPs. Generative tools that produce marketing content. Demos at industry conferences. Things that look like AI on a slide deck.
The companies that will win the next decade are quietly funding something else. Boring infrastructure that does not photograph well in an annual report and does not give a CEO anything compelling to say at a town hall.
That is the entire bet.
Why Boring Wins
The flashy AI investments fail a specific test. They depend on the quality of the underlying data, governance, and infrastructure to produce real value. Without those foundations, the demo works in a sandbox and falls apart in production.
The boring investments are exactly those foundations. They make the flashy investments possible. The companies that built them in 2023 will look like they suddenly pulled ahead in 2027. The ones that did not will be running pilots that do not scale, again, for the third year in a row.
What Boring Actually Looks Like
Five categories of investment that most pharma boards struggle to fund because none of them has a clear ROI on a quarterly basis.
1. Ontology and Semantic Grounding
The internal model of how your company describes products, indications, KOL relationships, regulatory documents, and clinical terminology. Without this, every AI agent produces inconsistent output because it has no grounded definition of the entities it is reasoning about.
Companies like Roche, AstraZeneca, and AbbVie have invested heavily in formal ontologies built on Basic Formal Ontology and the Pistoia Alliance Pharma General Ontology. None of these will appear in a press release. All of them will determine which company's AI agents are usable in regulated workflows three years from now.
2. Data Contracts and Pipeline Discipline
Every AI deployment depends on data flowing reliably from source systems into the AI layer. Most pharma data pipelines are built ad hoc, break frequently, and are not contracted between teams. The boring fix is data contracts. Schemas, SLAs, ownership, and breakage notifications.
This is unsexy plumbing. It is also the difference between an AI deployment that works on Tuesday and one that quietly breaks on Wednesday and no one notices for two weeks.
3. MLR Workflow Architecture
Medical, legal, and regulatory review is the choke point in pharma content production. Most companies still run this manually. The companies investing in structured MLR workflows, with content tagged, claims linked to evidence, and review cycles tracked, will be the only ones who can deploy AI content generation at scale without regulatory exposure.
Without this, generative AI for HCP content is a regulatory time bomb. With it, it is a 10x productivity unlock.
4. Human in the Loop Decision Logging
The ability to log every decision a human approved or overrode in an AI workflow. Decision, owner, timestamp, context. Without this, AI agents in regulated environments are not deployable. With it, they are auditable, and pharma can move with the same confidence that other industries have already moved with.
This is where I have spent most of my building time over the past year. The investment is not in the AI itself. It is in the audit and accountability layer around the AI.
5. HCP and Patient Data Models
The ability to link HCP behavior across CRM, claims, engagement, and prescribing data into a coherent model of each prescriber. Most pharma companies have these data sources in different systems with different IDs. Linking them is years of unglamorous work.
Without it, every AI personalization use case is approximate. With it, it is precise.
Why This Is Hard to Fund
Each of the five categories above has the same problem. The payoff is contingent on a future deployment the board has not approved yet. You are asking finance to fund the foundation of a building before the building is designed.
Foundation work fails standard ROI tests. Its value compounds across many future investments, none of which is guaranteed to happen. Most pharma CFOs will reject the request.
The companies that fund it anyway have one of three patterns. They reclassify the spend out of business unit P and L. They tie it to a near-term project that pays for itself and use the project budget to build reusable foundation. Or they wait for a high-profile failure and reallocate budget after the fact.
Most companies are still on the third pattern.
The Implication
In 2027, you will see two types of pharma AI announcements. Companies showing impressive AI deployments and companies struggling to scale pilots. The difference will not be the AI talent or the model selection. The difference will be what each company invested in between 2023 and 2026.
The boring bets are running now. Most of them are not announced. The companies running them will look like they suddenly pulled ahead. They did not. They just funded the unglamorous work three years before everyone else realized it mattered.
That is the entire game. Most companies are still funding the demo.
